X4 Pharmaceuticals Profitability Analysis

XFOR Stock  USD 1.01  0.03  3.06%   
Based on X4 Pharmaceuticals' profitability indicators, X4 Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in July. Profitability indicators assess X4 Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2016-12-31
Previous Quarter
-19.1 M
Current Value
-51.8 M
Quarterly Volatility
13.8 M
 
Covid
At this time, X4 Pharmaceuticals' Price To Sales Ratio is relatively stable compared to the past year. As of 06/03/2024, Days Sales Outstanding is likely to grow to 225.35, while Sales General And Administrative To Revenue is likely to drop 4.90. At this time, X4 Pharmaceuticals' Interest Income is relatively stable compared to the past year. As of 06/03/2024, Total Other Income Expense Net is likely to grow to about 6.8 M, though Operating Income is likely to grow to (102.1 M).
For X4 Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of X4 Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well X4 Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between X4 Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of X4 Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.
Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.67)
Return On Assets
(0.61)
Return On Equity
(4.89)
The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

X4 Pharmaceuticals Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining X4 Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare X4 Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
X4 Pharmaceuticals is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, X4 Pharmaceuticals' Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value X4 Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for X4 Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the X4 Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

XFOR Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

X4 Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
-4.89
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

X4 Pharmaceuticals

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.61
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

XFOR Return On Asset Comparison

X4 Pharmaceuticals is currently under evaluation in return on asset category among related companies.

X4 Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in X4 Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, X4 Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of X4 Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of X4 Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-107.1 K-101.7 K
Interest Income3.3 M3.5 M
Operating Income-107.5 M-102.1 M
Income Before Tax-101.1 M-96 M
Total Other Income Expense Net6.4 M6.8 M
Net Loss-86.8 M-82.4 M
Net Loss-101.2 M-96.1 M
Income Tax Expense78 K74.1 K
Net Interest Income-1.7 M-1.8 M
Net Loss-111.1 M-105.6 M
Non Operating Income Net Other-2 M-1.9 M
Change To Netincome7.1 M6.9 M
Net Loss(0.57)(0.60)
Income Quality 0.95  0.71 
Net Income Per E B T 1.00  1.12 

XFOR Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on X4 Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of X4 Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the X4 Pharmaceuticals' important profitability drivers and their relationship over time.

X4 Pharmaceuticals Profitability Trends

X4 Pharmaceuticals profitability trend refers to the progression of profit or loss within a business. An upward trend means that X4 Pharmaceuticals' profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is X4 Pharmaceuticals' gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

X4 Pharmaceuticals Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between X4 Pharmaceuticals different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards X4 Pharmaceuticals in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down X4 Pharmaceuticals' future profitability.

Use X4 Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

X4 Pharmaceuticals Pair Trading

X4 Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your X4 Pharmaceuticals position

In addition to having X4 Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Measuring and Control Equipment Thematic Idea Now

Measuring and Control Equipment
Measuring and Control Equipment Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
View All  Next Launch
When determining whether X4 Pharmaceuticals is a strong investment it is important to analyze X4 Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact X4 Pharmaceuticals' future performance. For an informed investment choice regarding XFOR Stock, refer to the following important reports:
Check out Your Current Watchlist.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for XFOR Stock analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Commodity Directory
Find actively traded commodities issued by global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stocks Directory
Find actively traded stocks across global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
To fully project X4 Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of X4 Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include X4 Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential X4 Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although X4 Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in X4 Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on X4 Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.